decitabine plus venetoclax is comparable to intensive chemotherapy in r/r aml
Published 3 years ago • 264 plays • Length 2:34Download video MP4
Download video MP3
Similar videos
-
1:17
venetoclax plus azacitidine vs intensive chemotherapy induction in fit patients with aml
-
9:17
comparing outcomes of 10-day decitabine with venetoclax vs. chemotherapy in aml based on fitness
-
1:17
decitabine, venetoclax and ponatinib in patients with advanced cml and ph aml
-
1:03
10-day astx727 (decitabine/cedazuridine) with venetoclax in the treatment of r/r aml
-
2:05
results from the phase i sal-relax trial: venetoclax plus cytarabine and mitoxantrone in r/r aml
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
2:43
venetoclax and intensive chemotherapy in npm1-mutated aml: findings from the caveat study
-
6:21
decitabine and venetoclax for aml
-
6:31
an overview of trials investigating asciminib in the treatment of ph cml
-
3:33
dna methylation and decitabine
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
4:15
phase ib/ii trial of quizartinib, decitabine and venetoclax in flt3-itd-mutated aml
-
1:36
the synergetic mechanism of pivekimab sunirine and venetoclax and its potential for treating aml
-
0:45
oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with aml
-
1:12
phase i study of ziftomenib with venetoclax or venetoclax/azacitidine or 7 3 in r/r aml
-
7:55
comparison of venetoclax-based versus non-venetoclax-based treatment regimens in aml
-
2:05
venetoclax with decitabine for high-risk aml and mds
-
0:44
predictors of poor response to azacitidine, venetoclax, and magrolimab in tp53-mutated aml
-
2:16
rationale for 10-day decitabine with venetoclax for high-risk aml
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
3:09
bleximenib combined with venetoclax and azacitidine in r/r aml with kmt2a or npm1 alterations
-
1:27
quizartinib, venetoclax, and decitabine in patients with flt3-itd aml: a phase i/ii trial